Expression of FGF19 is downregulated by lenvatinib, a multi-target drug, in CCA cells, thereby inactivating the PI3K/AKT pathway and inhibiting tumor cell proliferation, migration, and invasion 230. Here, AKT1 is linked to neoplasm.